First-in-Class cancer drug targets Hard-to-Treat tumors

This study tests an experimental oral drug called VMD-102 in people with advanced solid tumors, including liver, lung, kidney, skin (uveal melanoma), and colorectal cancers that have not responded to standard treatments. The drug works by blocking a specific protein (PKC epsilon) that may help cancer grow. The trial has two phases: first, to find the safest dose, and second, to see if the drug can shrink tumors or slow their growth. Researchers will also monitor side effects and measure how the drug behaves in the body.